SOUTH SAN FRANCISCO, Calif.,
Dec. 3, 2019 /PRNewswire/
-- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced
that management will present an update on the Company's business at
the first annual BioTuesdays Pre-JPM Virtual Conference on
Tuesday, December 10, 2019 at
3:00 p.m. EST / 12:00 p.m. PST.
The presentation will be broadcast live and archived on Titan's
website at www.titanpharm.com/news/events.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), based in South San Francisco, CA, is a commercial stage
company developing proprietary therapeutics with its ProNeura™
long-term, continuous drug delivery technology. The company's lead
product is Probuphine® (buprenorphine) implant, a novel and
long-acting formulation of buprenorphine for the long-term
maintenance treatment of opioid dependence. Approved by the U.S.
Food and Drug Administration in May
2016, Probuphine is the first and only commercialized
treatment of opioid dependence to provide continuous,
around-the-clock blood levels of buprenorphine for six months
following a single procedure. The ProNeura technology also has the
potential to be used in developing products for treating other
chronic conditions such as Parkinson's disease and hypothyroidism,
where maintaining consistent, around-the-clock blood levels of
medication may benefit the patient and improve medical outcomes.
For more information about Titan, please visit www.titanpharm.com.
release may contain "forward-looking statements" within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Such statements include, but are
not limited to, any statements relating to our product development
programs and any other statements that are not historical facts.
Such statements involve risks and uncertainties that could
negatively affect our business, operating results, financial
condition and stock price. Factors that could cause actual results
to differ materially from management's current expectations include
those risks and uncertainties relating to the commercialization of
Probuphine; the regulatory approval process; Titan's ability to
access capital; the development, testing, production and marketing
of our drug candidates; patent and intellectual property matters;
and strategic agreements and relationships. We expressly
disclaim any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements contained
herein to reflect any change in our expectations or any changes in
events, conditions or circumstances on which any such statement is
based, except as required by law.
President & CEO
View original content to download
SOURCE Titan Pharmaceuticals, Inc.